metastatic castration-resistant prostate cancer

Janux commences Phase Ib studies in trial for prostate cancer treatment
Clinical Trials Arena
Tue, 05/6/25 - 10:31 am
Janux Therapeutics
JANX007
clinical trials
prostate cancer
metastatic castration-resistant prostate cancer
AstraZeneca’s Truqap fails in another Phase III trial
Clinical Trials Arena
Wed, 04/30/25 - 11:25 am
AstraZeneca
Truqap
clinical trials
prostate cancer
metastatic castration-resistant prostate cancer
Vir Biotechnology Announces Encouraging Safety and Efficacy Data in Ongoing Dose Escalation Trials for Dual Masked T-Cell Engagers VIR-5818 in Solid Tumors and VIR-5500 in mCRPC
Stock Titan
Wed, 01/8/25 - 11:12 am
Vir Biotechnology
VIR-5818
solid tumors
VIR-5500
metastatic castration-resistant prostate cancer
ESMO 2024: Eli Lilly brings the competition to Novartis with new results in mCRPC
Clinical Trials Arena
Tue, 09/17/24 - 11:13 am
Eli Lilly
ESMO
lutetium zadavotide guraxetan
Astellas
Janssen
metastatic castration-resistant prostate cancer
Promontory’s prostate cancer trial reaches patient enrolment milestone
Clinical Trials Arena
Mon, 03/11/24 - 11:41 am
Promontory Therapeutics
clinical trials
PT-112
metastatic castration-resistant prostate cancer
prostate cancer
With negative FDA panel vote, AstraZeneca's Lynparza looks set for narrow nod in prostate cancer
Fierce Pharma
Mon, 05/1/23 - 10:16 am
AstraZeneca
Merck
Lynparza
metastatic castration-resistant prostate cancer
FDA Questions Efficacy of Merck-AstraZeneca’s Lynparza Ahead of Adcomm
BioSpace
Thu, 04/27/23 - 10:58 pm
Merck
AstraZeneca
FDA
Lynparza
metastatic castration-resistant prostate cancer
J&J claims first approval for PARP combo Akeega
Pharmaphorum
Mon, 04/24/23 - 10:22 am
JNJ
Janssen
Akeega
PARP inhibitors
metastatic castration-resistant prostate cancer
Europe
AstraZeneca, Merck hit with 3-month delay for Lynparza's FDA filing in first-line prostate cancer
Fierce Pharma
Thu, 12/15/22 - 11:01 am
AstraZeneca
Merck
Lynparza
FDA
metastatic castration-resistant prostate cancer
Why Janux Therapeutics Shares Rose 33.1% This Week
Motley Fool
Sun, 10/23/22 - 06:56 pm
Janux Therapeutics
oncology
JANX007
clinical trials
metastatic castration-resistant prostate cancer
Macrogenics takes another shot at a novel immune checkpoint
EP Vantage
Thu, 04/22/21 - 10:49 am
Macrogenics
MGC018
orlotamab
enoblituzumab
prostate cancer
metastatic castration-resistant prostate cancer
Exelixis initiates phase 3 trial of Cabozantinib/Atezolizumab combo in prostate cancer
Pharmaceutical Business Review
Wed, 07/1/20 - 11:03 am
Exelixis
cabozantinib
Cabometyx
Tecentriq
metastatic castration-resistant prostate cancer
clinical trials
AstraZeneca and Merck's Lynparza Improves Survival in Prostate Cancer with Specific Repair Gene Mutations
BioSpace
Sat, 04/25/20 - 12:10 am
AstraZeneca
Merck
clinical trials
Lynparza
metastatic castration-resistant prostate cancer
prostate cancer
Exelixis Reports Positive Results in Metastatic Castration-Resistant Prostate Cancer Study
Motley Fool
Wed, 02/12/20 - 10:27 am
Exelixis
prostate cancer
metastatic castration-resistant prostate cancer
cabozantinib
Cabometyx
Pfizer and Astellas Report Positive OS Data in Prostate Cancer Study
BioSpace
Tue, 02/11/20 - 11:45 pm
Pfizer
Astellas
prostate cancer
metastatic castration-resistant prostate cancer
Xtandi
Treating resistant prostate cancer by depriving a key hormone of its 'co-pilot'
Fierce Biotech
Thu, 08/29/19 - 12:22 pm
prostate cancer
metastatic castration-resistant prostate cancer
Carrick
C&7001
Marketing J&J eyes prostate cancer boost as FDA accepts Erleada for real-time review
Fierce Pharma
Fri, 05/3/19 - 10:43 pm
JNJ
Erleada
FDA
prostate cancer
metastatic castration-resistant prostate cancer
New 'peptoids' show promise in resistant prostate cancer
Fierce Biotech
Fri, 10/26/18 - 08:44 pm
peptoids
metastatic castration-resistant prostate cancer
Clovis' Rubraca leads to 44% ORR in Phase II for CRPC
BioCentury
Sat, 10/20/18 - 11:07 pm
Clovis Oncology
Rubraca
rucaparib
metastatic castration-resistant prostate cancer
Harpoon Therapeutics Begins Trial of Novel Immuno-Oncololgy Drug in Patients with Metastatic Castration-Resistant Prostate Cancer
CP Wire
Mon, 08/6/18 - 09:46 am
Harpoon Therapeutics
HPN424
metastatic castration-resistant prostate cancer

Pages